<VariationArchive VariationID="375746" VariationName="NM_000517.6(HBA2):c.95+2_95+6del" VariationType="Deletion" Accession="VCV000375746" Version="22" RecordType="classified" NumberOfSubmissions="8" NumberOfSubmitters="8" DateLastUpdated="2024-07-29" DateCreated="2017-03-02" MostRecentSubmission="2024-04-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="362629" VariationID="375746">
      <GeneList>
        <Gene Symbol="HBA2" FullName="hemoglobin subunit alpha 2" GeneID="3040" HGNC_ID="HGNC:4824" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="172876" stop="173710" display_start="172876" display_stop="173710" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="222845" stop="223708" display_start="222845" display_stop="223708" Strand="+" />
          </Location>
          <OMIM>141850</OMIM>
        </Gene>
        <Gene Symbol="LOC106804612" FullName="hemoglobin subunit alpha 2 recombination region" GeneID="106804612" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="170362" stop="173729" display_start="170362" display_stop="173729" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000517.6(HBA2):c.95+2_95+6del</Name>
      <CanonicalSPDI>NC_000016.10:173004:GAGGTGAGG:GAGG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="173005" stop="173009" display_start="173005" display_stop="173009" variantLength="5" positionVCF="173004" referenceAlleleVCF="AGAGGT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="223004" stop="223008" display_start="223004" display_stop="223008" variantLength="5" positionVCF="223003" referenceAlleleVCF="AGAGGT" alternateAlleleVCF="A" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.173009_173013del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.173009_173013del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.223008_223012del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.223008_223012del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_000006.1" sequenceAccession="NG_000006" sequenceVersion="1" change="g.33872_33876del">
            <Expression>NG_000006.1:g.33872_33876del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046165.1" sequenceAccession="NG_046165" sequenceVersion="1" change="g.2748_2752del">
            <Expression>NG_046165.1:g.2748_2752del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059186.1" sequenceAccession="NG_059186" sequenceVersion="1" change="g.1359_1363del">
            <Expression>NG_059186.1:g.1359_1363del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059271.1" sequenceAccession="NG_059271" sequenceVersion="1" change="g.5163_5167del">
            <Expression>NG_059271.1:g.5163_5167del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000517.6" sequenceAccession="NM_000517" sequenceVersion="6" change="c.95+2_95+6del" MANESelect="true">
            <Expression>NM_000517.6:c.95+2_95+6del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001575" Type="splice donor variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1225" sequenceAccession="LRG_1225">
            <Expression>LRG_1225:g.1359_1363del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1240" sequenceAccession="LRG_1240">
            <Expression>LRG_1240:g.5163_5167del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1240t1" sequenceAccession="LRG_1240t1">
            <Expression>LRG_1240t1:c.95+2_95+6del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000517.4" sequenceAccession="NM_000517" sequenceVersion="4" change="c.95+2_95+6delTGAGG">
            <Expression>NM_000517.4:c.95+2_95+6delTGAGG</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000517.6" sequenceAccession="NM_000517" sequenceVersion="6" change="c.95+2_95+6delTGAGG" MANESelect="true">
            <Expression>NM_000517.6:c.95+2_95+6delTGAGG</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA16602268" DB="ClinGen" />
        <XRef Type="rs" ID="41474145" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000517.6(HBA2):c.95+2_95+6del AND alpha Thalassemia" Accession="RCV000417225" Version="15">
        <ClassifiedConditionList TraitSetID="4863">
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2024-02-10" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000517.6(HBA2):c.95+2_95+6del AND not provided" Accession="RCV001800665" Version="19">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-10-31" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000517.6(HBA2):c.95+2_95+6del AND multiple conditions" Accession="RCV002502452" Version="8">
        <ClassifiedConditionList TraitSetID="50897">
          <ClassifiedCondition DB="MedGen" ID="C4693823">Erythrocytosis, familial, 7</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0700299">Heinz body anemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C3161174">Hemoglobin H disease</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-02-24" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-10" NumberOfSubmissions="8" NumberOfSubmitters="8" DateCreated="2017-03-02" MostRecentSubmission="2024-04-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15365991</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18473243</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20507641</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26771086</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29115104</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32498570</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">6946451</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7151175</ID>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301608</ID>
          <ID Source="BookShelf">NBK1435</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4863" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="50897" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5228" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Heinz body anemias</ElementValue>
                <XRef ID="Heinz+body+anemias/3265" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Heinz body hemolytic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Heinz body anemia</ElementValue>
                <XRef ID="HP:0005511" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007705" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10718" />
                <XRef ID="10718" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="178330" DB="Orphanet" />
              <XRef ID="C0700299" DB="MedGen" />
              <XRef ID="MONDO:0007705" DB="MONDO" />
              <XRef Type="MIM" ID="140700" DB="OMIM" />
              <XRef Type="primary" ID="HP:0005511" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
            <Trait ID="40029" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ERYTHROCYTOSIS, ALPHA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617981" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYTHEMIA, ALPHA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617981" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ERYTHROCYTOSIS 7</ElementValue>
                <XRef Type="Allelic variant" ID="141800.0018" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0144" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0087" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0090" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0126" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0182" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0098" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0016" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0109" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0015" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0023" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141850.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0063" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0145" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141800.0169" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Erythrocytosis, familial, 7</ElementValue>
                <XRef ID="MONDO:0054802" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ECYT7</ElementValue>
                <XRef Type="MIM" ID="617981" DB="OMIM" />
              </Symbol>
              <XRef ID="C4693823" DB="MedGen" />
              <XRef ID="MONDO:0054802" DB="MONDO" />
              <XRef Type="MIM" ID="617981" DB="OMIM" />
            </Trait>
            <Trait ID="12136" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hemoglobin H disease</ElementValue>
                <XRef ID="Hemoglobin+H+Disease/3294" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013512" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ALPHA-THALASSEMIA, HEMOGLOBIN H TYPE</ElementValue>
                <XRef Type="MIM" ID="613978" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HEMOGLOBIN H DISEASE, DELETIONAL</ElementValue>
                <XRef Type="MIM" ID="613978" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">HBH</ElementValue>
                <XRef Type="MIM" ID="613978" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="16829" />
                <XRef ID="16829" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000500397" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500318" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512435" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529069" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521288" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514598" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528544" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-High-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + High Barts Hb (&gt;20-25% Barts) or FAB3), Alpha (a) Thalassemia: Hb H Disease</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-High-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: High Barts Alpha Thalassemia Screening Result (FAB3; FA + Barts &gt; 20-25%), 2023</CitationText>
              </Citation>
              <XRef ID="93616" DB="Orphanet" />
              <XRef ID="C3161174" DB="MedGen" />
              <XRef ID="MONDO:0013512" DB="MONDO" />
              <XRef Type="MIM" ID="613978" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="968153" SubmissionDate="2016-12-29" DateLastUpdated="2022-10-01" DateCreated="2017-03-02">
        <ClinVarSubmissionID localKey="NM_000517.4:c.95+2_95+6delTGAGG|OMIM:604131" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV000503055" DateUpdated="2022-10-01" DateCreated="2017-03-02" Type="SCV" Version="2" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no classification provided</ReviewStatus>
          <GermlineClassification>not provided</GermlineClassification>
          <Citation>
            <ID Source="BookShelf">NBK1435</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA2" />
          </GeneList>
          <Name>alpha HphI</Name>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.4:c.95+2_95+6delTGAGG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0002312" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11808016</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2284678" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2020-02-10">
        <ClinVarSubmissionID localKey="2207414|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001160097" DateUpdated="2024-02-20" DateCreated="2020-02-10" Type="SCV" Version="5" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-10-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBA2 c.95+2_95+6del variant (HbVar ID: 1065) is a common pathogenic alpha thalassemia variant that disrupts the canonical splice donor site of intron 1 and alters splicing (Felber 1982, Lacerra 2004, Orkin 1981, see HbVar link). Heterozygosity for this variant is predicted to result in silent carrier status. Based on the information available, this variant is considered to be pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Felber BK et al. Abnormal RNA splicing causes one form of alpha thalassemia. Cell. 1982 Jul;29(3):895-902. PMID: 7151175. Lacerra G et al. Sequence variations of the alpha-globin genes: scanning of high CG content genes with DHPLC and DG-DGGE. Hum Mutat. 2004 Oct;24(4):338-49. PMID: 15365991. Orkin SH et al. Mutation in an intervening sequence splice junction in man. Proc Natl Acad Sci U S A. 1981 Aug;78(8):5041-5. PMID: 6946451.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.223008_223012del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
          <SubmissionName>Aug 2019 ARUP</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4079514" SubmissionDate="2022-02-09" DateLastUpdated="2022-02-13" DateCreated="2022-02-13">
        <ClinVarSubmissionID localKey="NM_000517.6:c.95+2_95+6del|Alpha thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002093843" DateUpdated="2022-02-13" DateCreated="2022-02-13" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-08-17">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.6:c.95+2_95+6del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Alpha thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5458200" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000517.6:c.95+2_95+6del|OMIM:140700;604131;613978;617981" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002813702" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.6:c.95+2_95+6del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="140700" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604131" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613978" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617981" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4924844" SubmissionDate="2022-05-16" DateLastUpdated="2023-03-04" DateCreated="2022-05-21">
        <ClinVarSubmissionID localKey="GDXSV:226488" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002513024" DateUpdated="2023-03-04" DateCreated="2022-05-21" Type="SCV" Version="2" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-04-18">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Common variant reported in individuals of Mediterranean ethnicity with HbH disease (Orkin et al., 1981; Mesbah-Amroun et al., 2008; Farra et al., 2014; de la Fuent-Gonzalo et al., 2019); Canonical splice site variant predicted to result in a null allele in a gene for which loss-of-function is a known mechanism of disease; Also denoted as IVS1-5nt and alpha-Hph due to alternative nomenclature; This variant is associated with the following publications: (PMID: 6946451, 15365991, 26771086, 31025160, 7151175, 25284125, 18473243, 23215864, 31589614, 29627922)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA2" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="16" alternateAllele="-" referenceAllele="TGAGG" start="223008" stop="223012" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:758258</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_104_20220504054205</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5002955" SubmissionDate="2023-12-11" DateLastUpdated="2023-12-17" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="sa_pathology/genomics_unit/vc36353" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002557001" DateUpdated="2023-12-17" DateCreated="2022-08-08" Type="SCV" Version="3" SubmitterName="Genetics and Molecular Pathology, SA Pathology" OrgID="506043" OrganizationCategory="laboratory" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">7151175</ID>
          </Citation>
          <Comment>The HBA2 c.95+2_95+6del variant is classified as Pathogenic (PVS1, PS4, PP4) The HBA2 c.95+2_95+6del variant is located in a splice donor region. Computational predictions support a deleterious effect on splicing and a likely disruption of the protein reading frame and non-sense mediated decay of the resulting protein product (PVS1). This pentanucleotide HBA2:c.95+2_95+6delTGAGG deletion occurs within the 5' splice junction of the first intervening sequence, preventing normal RNA splicing. This mutation is listed on the Haemoglobin Variant Database as an alpha thalassaemia mutation (PMID: 7151175) (PS4). Present in numerous internal database patients as per alamut with consistent symptoms of alpha thalassaemia carrier. No functional studies performed. The clinical features of this case are highly specific for HBA1/2, and this patient has a well-defined syndrome with little overlap with other clinical presentations (PP4). Variants in HBA1/2 are highly specific for alpha thalassaemia. The variant has been reported in dbSNP (rs41474145) and has been reported as Pathogenic by other diagnostic laboratories (ClinVar Variation ID: 375746). It has been reported in HGMD (CD810004).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_4327</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.6:c.95+2_95+6delTGAGG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604131" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_33</SubmissionName>
          <SubmissionName>submission_36</SubmissionName>
          <SubmissionName>submission_40</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4013340" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2022-01-03">
        <ClinVarSubmissionID localKey="S8442|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002047269" DateUpdated="2024-01-06" DateCreated="2022-01-03" Type="SCV" Version="3" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2020-09-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26771086</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32498570</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29115104</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20507641</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">6946451</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">7151175</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18473243</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15365991</ID>
          </Citation>
          <Comment>The c.95+2_95+6delTGAGG pathogenic variant in the alpha2-globin (HBA2) gene is the deletion of nucleotides 2 to 6 (TGAGG) of intron 1. This deletion occurs in the splice-donor site and prevents normal splicing of the alpha2-globin mRNA (see , and PMIDs: 6946451 (1981), 7151175 (1982), and 20507641 (2010)), and has been reported in individuals affected with alpha thalassemia in the published literature (PMIDs: 6946451 (1981), 7151175 (1982), 15365991 (2004), and 29115104 (2018)). An in vitro study reports no functional alpha-globin protein is synthesized from the mutant alpha2-globin allele (PMID: 7151175 (1982)).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000517.4:c.95+2_95+6del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10813355</SubmissionName>
          <SubmissionName>SUB12490872</SubmissionName>
          <SubmissionName>SUB14108248</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9056511" SubmissionDate="2024-04-19" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="104765920|Orphanet:ORPHA846" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004848829" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">6946451</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15365991</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">7151175</ID>
          </Citation>
          <Comment>The c.95+2_95+6del variant in HBA2 is a common pathogenic variant for alpha thalassemia in the Mediterranean region (Felber 1982 PMID: 7151175, Lacerra 2004 PMID: 15365991, Orkin 1981 PMID: 6946451, HbVar database: https://globin.bx.psu.edu/hbvar/menu.html; HbVarID:1065). This variant has been reported by other clinical laboratories in ClinVar (Variation ID 375746) and was absent from large population studies (gnomAD, v.3.1.2). This deletion affects the canonical splice site position (+2) and is predicted to cause altered splicing leading to an abnormal or absent protein. Biallelic loss of function of the HBA2 gene is an established disease mechanism in autosomal recessive alpha thalassemia. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive alpha thalassemia. ACMG/AMP Criteria applied: PVS1_Strong, PM3_Strong, PM2_supporting.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000517.6:intron 1</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.10:g.173009_173013delTGAGG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA846" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14389831</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5458200" TraitType="Disease" MappingType="XRef" MappingValue="140700" MappingRef="OMIM">
        <MedGen CUI="C0700299" Name="Heinz body anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5458200" TraitType="Disease" MappingType="XRef" MappingValue="617981" MappingRef="OMIM">
        <MedGen CUI="C4693823" Name="Erythrocytosis, familial, 7" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4013340" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5002955" TraitType="Disease" MappingType="XRef" MappingValue="604131" MappingRef="OMIM">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5458200" TraitType="Disease" MappingType="XRef" MappingValue="604131" MappingRef="OMIM">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="968153" TraitType="Disease" MappingType="XRef" MappingValue="C0002312" MappingRef="MedGen">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4924844" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4079514" TraitType="Disease" MappingType="Name" MappingValue="Alpha thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5458200" TraitType="Disease" MappingType="XRef" MappingValue="613978" MappingRef="OMIM">
        <MedGen CUI="C3161174" Name="Hemoglobin H disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2284678" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9056511" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA846" MappingRef="Orphanet">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2021-05-28">SCV001528507</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

